XBiotech Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
XBIT$1.89+1.1%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 (unaudited) and 2024 (unaudited)
(in thousands)
| Six Months Ended June 30, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| (unaudited) · (unaudited) | |||
| Operating activities | |||
| Net loss | $(12,640) | $(23,008) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation | 881 | 867 | |
| Foreign exchange (gain) loss | (3,365) | 2,136 | |
| Share-based compensation expense | 3,436 | 760 | |
| Changes in operating assets and liabilities: | |||
| Income tax receivable | - | (48) | |
| Accrued interest receivable | 220 | (10) | |
| Prepaid expenses and other current assets | (281) | (356) | |
| Accounts payable | (795) | (817) | |
| Accrued expenses | (222) | 1,847 | |
| Income tax payable | 57 | 51 | |
| Net cash used in operating activities | (12,709) | (18,578) | |
| Investing activities | |||
| Purchase of property and equipment | (145) | (882) | |
| Net cash used in investing activities | (145) | (882) | |
| Financing activities | |||
| (Payment on) proceeds from convertible loan, related party | (10,000) | 10,000 | |
| Payment on convertible loan, third party | (250) | ||
| Proceeds from issuance of common stock under stock option plan | - | 103 | |
| Net cash (used in) provided by financing activities | (10,250) | 10,103 | |
| Effect of foreign exchange rate on cash and cash equivalents | 3,365 | (2,136) | |
| Net change in cash and cash equivalents | (19,739) | (11,493) | |
| Cash and cash equivalents, beginning of period | 172,677 | 200,023 | |
| Cash and cash equivalents, end of period | $152,938 | $188,530 | |
| Supplemental Information: | |||
| Accrued purchases of property and equipment | $3 | $4 | |
| Cash paid for interest | $486 | $ | - |
Notes to Condensed Consolidated Financial Statements (Unaudited)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.